The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374 on June 26, 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the impact factor is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Other journal metrics for JITC can be found on the journal website.
JITC seeks submissions to its Basic Tumor Immunology section
Edited by Cornelis J.M. Melief, MD, PhD, the Basic Tumor Immunology section publishes on topics that include Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Submit your manuscript today to the open access journal.
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this $2,400 value member benefit, contact SITC at +1 414-271-2456 or JITCEditor@sitcancer.org for your member code prior to submission.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available.
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers have not been studied in melanoma.
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens...
Memorial Sloan Kettering Cancer Center invites you to attend the 2018 Annual Cancer Treatment-Related Adverse Events Symposium on Friday-Saturday, October 26-27 , at Zuckerman Research Center in New York. Systemic anticancer therapies including ...
We are currently organizing the 8 th InterAmerican Oncology Conference, "Current Status and Future of Anti-Cancer Therapies" will take place on October 17 th and 18 th , 2019 in Buenos Aires, Argentina.
Dres. Alex Adjei (Mayo Clinic, USA), Román ...
Usage of CRISPR/Cris9, an RNA guided DNA gene editing technology has powerful manipulative abilities. It has a special place in genetic engineering in its development. There is current development of this technology for therapeutic applications, particularly ...
Hi all- Fight Colorectal Cancer (CRC) will be hosting a webinar next Wednesday August 8th at 1:30p EST around biomarkers such as BRAF and HER2, as well as sidedness and what these mean for tailoring treatment for colorectal cancer patients. Be sure ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org